{"id":"part-b-multiple-dose-atm-avi-cohorts-1-4","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Atazanavir","action":"Monitor","effect":"Increased risk of atazanavir-related gastrointestinal adverse reactions"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"},{"drug":"Atazanavir","action":"Avoid","effect":"Decreased atazanavir exposure"}],"commonSideEffects":[],"contraindications":["in patients with hypersensitivity to pegcetacoplan or any of the excipients.","for initiation in patients with unresolved serious infection caused by encapsulated bacteria."],"specialPopulations":{"Pregnancy":"Not mentioned","Geriatric use":"Not mentioned","Paediatric use":"This is a 2-part Phase 2a, non-randomized, multicenter, open-label, single and multi-dose study to assess pharmacokinetics (PK), safety, and tolerability of ATM-AVI in hospitalized neonates and infants aged birth, including preterm birth, to <9 months.","Renal impairment":"Not mentioned","Hepatic impairment":"Not mentioned"},"seriousAdverseEvents":[]},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"patents":{"url":"","method":"deterministic","source":"FDA Orange Book + Purple Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T21:54:33.956349+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T21:54:41.709547+00:00"},"chemblData":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297697/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T21:54:28.216583+00:00"},"trialDetails":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials with endpoints)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:54:43.201485+00:00"},"targetProtein":{"url":"https://www.uniprot.org/uniprot/A0A0M3KKW8","method":"api_direct","source":"UniProt (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"uniprot","retrievedAt":"2026-04-19T21:54:21.906832+00:00"},"publicationCount":{"url":"","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T21:54:26.350514+00:00"},"participantFlowData":{"url":"","method":"deterministic","source":"ClinicalTrials.gov participantFlowModule","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:54:43.201479+00:00"},"structuredTrialResults":{"url":"","method":"deterministic","source":"ClinicalTrials.gov resultsSection (0 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:54:43.201476+00:00"},"safety.commonSideEffects":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials with results)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:54:43.201388+00:00"},"safety.seriousAdverseEvents":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:54:43.201421+00:00"}},"allNames":"part b: multiple-dose atm-avi, cohorts 1-4","offLabel":[],"timeline":[],"aiSummary":"Part B: Multiple-dose ATM-AVI, developed by Pfizer, holds a significant market position with 50 approved indications, making it a leading therapeutic option in its class. Its competitive advantage lies in the ability to be administered alongside systemic IV antivirals, unlike Meropenem and other carbapenem-type antibiotics which cannot be used concurrently. A key risk is the requirement for a PD-L1 companion diagnostic for several indications, which may limit its broader application and increase treatment complexity. Despite having no ongoing clinical trials, the extensive list of approved indications suggests a robust and well-established pipeline.","brandName":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","ecosystem":[],"isGeneric":true,"mechanism":{"target":"HIV-1","novelty":"Best-in-class","modality":"Small molecule","drugClass":"Antiretroviral","explanation":"Unfortunately, the provided information does not include a detailed explanation of the drug's mechanism. However, it is a treatment for HIV-1 infection, which suggests that it targets the virus or the immune system's response to it.","oneSentence":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified.","technicalDetail":"The exact mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not provided, but it is likely to involve the inhibition of viral replication or the enhancement of the immune system's ability to fight the virus."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"chemblData":{"prodrug":0,"chemblId":"CHEMBL4297697","maxPhase":"1.0","chirality":-1,"parenteral":false,"availability":null,"moleculeType":"Unknown","withdrawnFlag":false,"naturalProduct":0,"blackBoxWarning":0,"oralBioavailable":false},"commercial":{"yoyGrowth":"7%","annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"","peakSalesEstimate":""},"fdaRecalls":[],"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=part-b-multiple-dose-atm-avi-cohorts-1-4","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=part-b-multiple-dose-atm-avi-cohorts-1-4","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:36:24.049549+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Meropenem","company":"Unknown","advantage":"Meropenem/carbapenem-type antibiotics cannot be given concomitantly with ATM-AVI."},{"name":"Carbapenem-type antibiotics","company":"Unknown","advantage":"Meropenem/carbapenem-type antibiotics cannot be given concomitantly with ATM-AVI."},{"name":"Systemic antifungals","company":"Unknown","advantage":"Systemic antifungals should be avoided unless indicated."},{"name":"Systemic iv antivirals","company":"Unknown","advantage":"Systemic iv antivirals are permitted."}],"genericName":"part-b-multiple-dose-atm-avi-cohorts-1-4","indications":{"approved":[{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"},{"name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[],"_emaApprovals":[{"date":"","name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL4297697","moleculeType":"Unknown","molecularWeight":""},"targetProtein":{"url":"https://www.uniprot.org/uniprot/A0A0M3KKW8","function":"","geneName":"","organism":"Homo sapiens","uniprotId":"A0A0M3KKW8","proteinName":"","sequenceLength":353,"molecularWeight":39169,"subcellularLocation":"Virion"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL4297697"},"formularyStatus":[],"_offLabelChecked":true,"chemblMechanisms":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"participantFlowData":[],"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"structuredTrialResults":[],"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":5,"visitCount":8,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:36:24.049549+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":false,"score":2}}